Pharmaceutical companies are vying to lay out, and a number of domestically produced new hypoglycemic drugs will enter the market

 Diabetes mellitus is a metabolic disease characterized by high blood sugar clinically, which can be specifically divided into type 1 diabetes, type 2 diabetes, and gestational diabetes
.
With the increasing aging of the population in China, the continuous improvement of people's living standards, and the influence of unhealthy life>
.
According to relevant data, China's diabetes drug market will exceed 52 billion yuan in 2020
.
In the face of huge market demand, many pharmaceutical companies are also vying to deploy in the field of diabetes drugs
.
Among them, on October 19, the original innovative drug "siglita sodium" independently developed and produced by Microchip Biosciences was approved by the National Medical Products Administration for listing, which has attracted market attention
.
The brand name of Sieglipta Sodium Tablets from Microchip Biosciences is Bilessglu/Bilessglu, and the specification is 16mg
.
Single medicine is suitable for diet control and exercise to improve blood sugar control in adults with type 2 diabetes
.
According to its announcement, sitaglipta sodium is a new molecular entity drug with a novel mechanism discovered by the company.
It is a new type of insulin sensitizer that has completed phase III clinical trials and has been declared for marketing (NDA) for type 2 diabetes
.
Siglipta sodium can not only restore the sensitivity of diabetic patients to insulin, continuously control blood sugar, but also treat the lipid metabolism disorders that patients often accompany
.
Boosted by this benefit, on October 19, Microchip Biotechnology rose nearly 6%, with a new total market value of 16.
9 billion yuan
.
It is understood that in recent years, as domestic pharmaceutical companies have accelerated their research and development, a number of new hypoglycemic drugs have entered the market to compete with imported new drugs
.
At present, in addition to the approval of Microchip's new drug for the market, Hengrui Medicine's Repagliptin Phosphate Tablets and Proline Henggligliflozin Tablets are currently under review and approval, and are also attracting attention from the industry
.
Among them, Repagliptin phosphate tablets are a DPP-4 inhibitor, similar in structure to the listed sitagliptin.
In 2020, the global sales of sitagliptin will remain above US$3 billion, and the market potential is considerable; proline Acid Henggliflozin tablets are expected to become the first original SGLT-2 inhibitor in China
.
The author also learned that Hua Medicine dozaglietin tablets are the first new class 1 hypoglycemic drug to be produced this year.
This new drug is also a glucokinase activator (GKA) diabetes treatment drug that has been submitted for new drug marketing applications worldwide.
And it is expected to be listed first in China
.
Looking back over the more than ten years of research and development of Dopagliflozin, Hua Medicine has not only established a scientific theory of "repairing sensing, remodeling problems, and treating diabetes from the source", but also accumulated a lot of research results in clinical trials: Two phase III registration clinical studies have shown that doxagliptin monotherapy and combined with metformin have shown long-term stable efficacy and good safety, can take effect quickly, significantly reduce postprandial blood glucose, etc.
, and at the same time in the study period Inside, doxagliptin can improve the secretion of insulin prime minister, improve β cell function, reduce insulin resistance and so on
.
According to the industry, the number of diabetic patients in China continues to grow rapidly, and the huge unmet demand urgently needs effective innovative drug treatments to help patients restore the steady-state balance of blood sugar
.
Now with the good news from many companies such as Microchip, Hengrui Medicine, Hualing Medicine, the diabetes medicine market will be further improved, and patients will also benefit further
.
However, some analysts also pointed out that as more products are approved for listing in the future, industry companies will also usher in more intense market competition
.